Community-Acquired Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: Management and Prevention
- 391 Downloads
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) was a rare phenomenon until the past decade; now CA-MRSA is endemic in many communities and is the most common cause of skin and soft tissue infections presenting to emergency rooms. CA-MRSA is distinct from its hospital-acquired counterpart, and has caused devastating infections in many healthy individuals. The epidemiology of CA-MRSA continues to evolve, and the challenge is to use the most appropriate and effective therapeutic and preventative strategies against this pathogen. This article reviews the current epidemiology of CA-MRSA, its definitions, and common clinical manifestations in the community. The article also summarizes current therapeutic options for CA-MRSA as well as strategies to reduce the transmission and the impact of CA-MRSA in both community and health care settings.
KeywordsMethicillin-resistant Staphylococcus aureus MRSA, Community-acquired CA-MRSA Skin and soft tissue infection Decolonization Management Prevention Treatment
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as:•Of importance••Of major importance
- 9.Munckhof WJ, Nimmo GR, Carney J, et al. Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study. Eur J Clin Microbiol Infect Dis. 2008;27:355–64.PubMedCrossRefGoogle Scholar
- 12.Centers for Disease Control and Prevention: Diagnosis and Testing of MRSA Infections. Available at: http://www.cdc.gov/mrsa/diagnosis/index.html. Accessed 04/19/2011.
- 22.• Golding GR, Levett PN, McDonald RR, et al.: A comparison of risk factors associated with community-associated methicillin-resistant and -susceptible Staphylococcus aureus infections in remote communities. Epidemiol Infect. 2010;138:730–7. An interesting article that compares and contrasts risk factors of infection by CA-MRSA versus CA-MSSA infections. PubMedCrossRefGoogle Scholar
- 26.Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis. 2007;44:471–82.PubMedCrossRefGoogle Scholar
- 30.••. Liu C, Bayer A, Cosgrove SE, et al.: Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–92. This important article summarizes the current recommendations for treatment of MRSA infections from the Infectious Diseases Society of America (IDSA). PubMedCrossRefGoogle Scholar
- 31.•• Chua K, Laurent F, Coombs G, et al.: Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician’s guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52:99–114. This is a splendid article that describes the evolution of CA-MRSA infections, current molecular epidemiology and implications for therapy. PubMedCrossRefGoogle Scholar
- 34.•• Wilcox MH, Tack KJ, Bouza E, et al.: Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48:203–12. This key article showed non-inferiority of linezolid compared to vancomycin for complicated skin and skin-structure infections. However, the study also found an increased failure rate of linezolid when used for Gram-negative catheter-associated bloodstream infections. PubMedCrossRefGoogle Scholar
- 39.• Corey GR, Wilcox M, Talbot GH, et al.: Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641–50. This article reported the combined analysis of data from two parallel studies of ceftaroline compared with vancomycin and aztreonam for treatment of complicated skin and soft tissue infections (CANVAS I & II). PubMedCrossRefGoogle Scholar
- 40.Centers for Disease Control and Prevention: MRSA and the Workplace. Available at: http://www.cdc.gov/niosh/topics/mrsa/. Accessed 4/21/2011.
- 43.Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44:178–85.PubMedCrossRefGoogle Scholar
- 44.Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother. 2007;51:3591–8.PubMedCrossRefGoogle Scholar
- 46.Nerandzic MM, Cadnum JL, Pultz MJ, Donskey CJ: Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms. BMC Infect Dis. 10:197.Google Scholar
- 47.Rutala WA, Gergen MF, Weber DJ: Room decontamination with UV radiation. Infect Control Hosp Epidemiol. 31:1025–9.Google Scholar